INSANE: Cormedix org - The Real Truth

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms

CorMedix (NASDAQ:CRMD) CEO Joe said the company is preparing for several potential commercial and regulatory catalysts across its infectious disease and dialysis-related portfolio, including a possible expansion of REZZAYO into fungal infection prophylaxis and continued work to sustain DefenCath uti

MarketBeat · May 22

CorMedix Q1 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported sharply higher first-quarter 2026 revenue and profit, driven by continued adoption of DefenCath and the addition of products from its Melinta acquisition, while management raised its full-year financial outlook and outlined key pipeline developments. Chairman and Chi

MarketBeat · May 14

High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026

2026 could be a pivotal year for three biotech names, including a standout in the hemodialysis space and two emerging companies with strong pipelines.

MarketBeat · Jan 19

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · Aug 9, 2022

Cormedix: Q1 Earnings Insights

Cormedix (NASDAQ:CRMD) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Cormedix beat estimated earnings by 18.18%, reporting an EPS of $-0.18 versus an estimate of $-0.22.

Benzinga · May 12, 2022

Cormedix's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q4, Cormedix's (NASDAQ:CRMD) reported sales totaled $56.40 thousand. Despite a 9.08% increase in earnings, the company posted a loss of $7.79 million.

Benzinga · Mar 30, 2022

CorMedix Refiles DefenCath US Application For Catheter-Related Bloodstream Infections

CorMedix Inc (NASDAQ: CRMD) has resubmi

Benzinga · Feb 28, 2022